PharmAbcine, Inc., a biotechnology company, develops human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. PharmAbcine, Inc. is headquartered in Daejeon, South Korea.
461-8, Daejeon BioventureTown
PharmAbcine, Inc. Presents at BIO-Europe 2015, Nov-04-2015 10:15 AM
Sep 21 15
PharmAbcine, Inc. Presents at BIO-Europe 2015, Nov-04-2015 10:15 AM. Venue: Munich, Germany.
PharmAbcine, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:00 AM
Jan 29 15
PharmAbcine, Inc. Presents at BIO-Europe Spring 2015, Mar-10-2015 11:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
3SBio Inc. Enters into an Exclusive License with PharmAbcine, Inc
Nov 19 14
3SBio Inc. announced it has entered into an exclusive license with PharmAbcine Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. The deal included undisclosed upfront, milestone and royalty payments. Angiogenesis is correlated with disease progression and poor prognosis in many tumor types, such as colon, lung, breast and gastric cancers. VEGF and KDR (VEGFR2) are over-expressed in most malignant tumors, such as gastric, liver, NSCLC, ovarian, brain, colorectal, and breast cancers and their signaling is key regulator for tumor angiogenesis. Researchers from PharmAbcine have developed Tanibirumab, an anti-VEGFR2/KDR fully human monoclonal antibody to treat solid tumors. Tanibirumab binds KDR and blocks binding of VEGFR ligands, including VEGF-A, VEGF-C and VEGF-D. Consequently, Tanibirumab inhibits ligand-stimulated activation of KDR, therefore inhibits ligand-induced angiogenesis, proliferation, and migration of human endothelial cells. Tanibirumab had demonstrated anti-angiogenic efficacy against several cancer types and shown cross-species cross reactivity in multiple preclinical animal models including breast cancer, glioblastoma (GBM), lung cancer, colon cancer, and hepatocellular carcinoma (HCC). In November 2011, an open-label, non-randomized, dose-escalating phase I trial began to assess the safety and pharmacokinetics of Tanibirumab, administered intravenously, in 26 patients in Korea with advanced or metastatic cancer. The trial was finished in November 2013, with good safety and efficacy results. A phase II study of Tanibirumab in GBM is being planned.